http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Sym, Sun Jin,Ryu, Min-Hee,Lee, Jae-Lyun,Chang, Heung Moon,Kim, Tae Won,Lee, Sung Sook,Lee, Jung Shin,Kang, Yoon-Koo Lippincott Williams Wilkins, Inc. 2008 American journal of clinical oncology: cancer clin Vol.31 No.2
OBJECTIVES:: We retrospectively assessed the combination of biweekly irinotecan with 5-fluorouracil (5-FU), and leucovorin (LV) as salvage chemotherapy in patients with advanced gastric cancer (AGC) previously treated with fluoropyrimidine (F), platinum (P), and taxane (T). METHODS:: Between October 2003 and February 2006, all 131 patients with AGC were treated with irinotecan (150 mg/m on day 1), along with either FOLFIRI-1 (ie, LV (20 mg/m bolus) before 5-FU (1000 mg/m continuous infusion over 6-hour) on days 1–2), or FOLFIRI-2 (ie, LV (20 mg/m bolus) before 5-FU (400 mg/m bolus) followed by 22-hour continuous infusion of 600 mg/m on days 1–2), or FOLFIRI-3 (ie, 5-FU (400 mg/m bolus) followed by 46-hour continuous infusion of 2400 mg/m 5-FU and 100 mg/m LV). Cycles were repeated every 2 weeks. RESULTS:: The median age of the patients was 52 years (range, 19–70 years). Patients received a median of 4 cycles of chemotherapy (range, 1–21 cycles). Of the 97 patients with measurable disease, 1 (1.0%) achieved a complete response, and 11 (11.3%) achieved partial responses, making the overall response rate 12.3%. The median time to progression (TTP) was 2.2 months (95% CI, 1.9–2.6 months) and the median overall survival (OS) was 6.2 months (95% CI, 5.6–6.9 months). Good performance status (P = 0.046), fewer metastatic sites (P < 0.001), and longer time to progression of previous chemotherapy (P = 0.006) were independent prognostic factors affecting OS. OS was longer with the FOLFIRI-1 regimen but not with statistical significance (P = 0.064). The treatments were generally well tolerated. CONCLUSIONS:: In actual clinical practice, biweekly irinotecan with 5-FU and LV had modest activity and tolerability in AGC patients previously treated with F, P, and T.
Sym, Sun Jin,Ryu, Min-Hee,Lee, Jae-Lyun,Chang, Heung Moon,Kim, Tae-Won,Kim, Hee Cheol,Kim, Ki Hun,Yook, Jeong Hwan,Kim, Byung Sik,Kang, Yoon-Koo Wiley Subscription Services, Inc., A Wiley Company 2008 Journal of surgical oncology Vol.98 No.1
<B>Background</B><P>We investigated the role of surgical intervention for advanced GIST after imatinib.</P><B>Methods</B><P>Among 256 patients treated with imatinib for advanced GIST, the medical records of the 34 patients who underwent surgery of residual tumors after imatinib treatment were reviewed.</P><B>Results</B><P>Surgery was performed on 24 patients with responsive disease (RD) after imatinib, on 3 with focal progressive disease (FP), and on 7 with generalized progressive disease (GP). All gross tumors were completely resected in 19/24 (79%), 1/3 (33%), and 1/7 (14%) patients, respectively. Disease status at surgery was associated with prognosis after surgery; with a median follow-up of 25.7 months, the median progression-free survival of patients resected for RD, FP, and GP were 27.8 months (95% CI, 17.8–37.8 months), 5.1 months (95% CI, 4.7–5.6 months), and 3.3 months (95% CI, 2.7–3.9 months), respectively (P < 0.001). Median overall survival was not reached in patients resected for RD, and was 22.5 months (95% CI, 1.4–43.0 months) and 23.5 months (95% CI, 3.0–43.9) for patients resected for FP and GP, respectively (P < 0.001).</P><B>Conclusion</B><P>Surgical resection of tumors responsive to imatinib may be beneficial in patients with advanced GIST. Debulking surgery, however, is not recommended for patients who have already developed imatinib resistance. J. Surg. Oncol. 2008;98:27–33. © 2008 Wiley-Liss, Inc.</P>
심선진 ( Sun Jin Sym ) 대한내과학회 2015 대한내과학회지 Vol.89 No.5
Metastatic bladder cancer is generally incurable, with a median survival of 14 to 15 months under a modern chemotherapy regimen. Cisplatin-based chemotherapy, including the combination regimens methotrexate-vinblastine-doxorubicin-cisplatin and gemcitabine-cisplatin, are the standard first-line therapy. Despite response rates of 40% to 60% achieved, most patients’ cancers progress after about 8 months. Second-line single agents have only marginal efficacy after cisplatin-based treatment failure, with objective response rates of 5% to 20% and a median progression-free survival of only 3 to 4 months. Moreover, there is little evidence that second-line systemic treatment can substantially improve overall survival or quality of life. Agents targeting growth, survival, and proliferation pathways have been added to cytotoxic therapy with limited added benefits to date. Drugs that modulate the host immune response to cancer-associated antigens, including immunologic checkpoint blockade by antibodies against programmed cell death protein-1 or its ligands, appear promising, and multiple new therapeutic approaches are being pursued. In addition, the receptor tyrosine kinase/Ras pathway and the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of the rapamycin pathway represent potential therapeutic targets for advanced disease, and novel agents are in development. (Korean J Med 2015,89:515-521)
Junshik Hong,Ae Jin Kim,Jin Sun Park,이석호,이규찬,Sun Jin Sym,조은경,Dong Bok Shin,이재훈,박진희 대한혈액학회 2010 Blood Research Vol.45 No.4
Background Standard treatment for stage I or non-bulky stage II diffuse large B-cell lymphoma (DLBCL) has been either a brief course of chemotherapy plus involved-field radiotherapy (IFRT) or prolonged cycles of chemotherapy. The introduction of rituximab has necessitated re-evaluation of the treatment for limited disease (LD) DLBCL. Methods Thirty-nine LD DLBCL patients (median age, 52 years; range, 24-85) treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) were retrospectively analyzed. Treatment outcomes were evaluated, and toxicity, event-free survival (EFS), and overall survival (OS) were compared according to the treatment and risk factors. Results The median follow-up duration was 34.6 months (range, 9.1-65.4). The 3-year EFS and OS were 76.0% and 86.0%, respectively. Among the 36 patients who underwent either 3-4 cycles of R-CHOP followed by IFRT (N=22) or 6-8 cycles of R-CHOP (N=14), there was no difference in the 3-year EFS (79.4% vs. 71.6%, P=0.638) and 3-year OS (85.7% vs. 92.9%, P=0.732). Severe neutropenia and neutropenic fever were more frequent in patients treated with R-CHOP alone, with 1 treatment-related mortality. Among the IFRT patients, 1 required hospital admission for IFRT-related complications. No events or deaths were reported among patients without adverse risk factors. Conclusion The difference in outcomes between the 2 treatment options was not significant. Analysis of treatment outcomes suggested that baseline characteristics and expected toxicities should be considered in LD DLBCL treatment. Further studies are needed to define the optimal treatment in the rituximab era.